Franz-Werner Haas, CureVac CEO (Thomas Kienzle/AFP via Getty Images)

'No rea­son to slow down any­thing here': Cure­Vac plans to march on with Covid-19 vac­cine af­ter piv­otal fail­ure

The day af­ter Cure­Vac re­vealed its mR­NA vac­cine failed a piv­otal tri­al, crush­ing the com­pa­ny’s stock, a group of an­a­lysts tuned in­to the com­pa­ny call with vari­a­tions of the same ques­tion: What’s next for CVn­CoV?

Cure­Vac’s shares $CVAC were down near­ly 49% on Thurs­day morn­ing, af­ter an­nounc­ing an in­ter­im vac­cine ef­fi­ca­cy of just 47% against Covid-19 dis­ease of any sever­i­ty. The com­pa­ny blamed its ef­fi­ca­cy is­sues on emerg­ing vari­ants, ar­gu­ing that the vac­cine’s late en­try left re­searchers in an “in­creas­ing­ly chal­leng­ing vari­ant-rich en­vi­ron­ment,” with 13 strains cir­cu­lat­ing, CEO Franz-Wern­er Haas said on a call with in­vestors Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.